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Contemporary healthcare has progressed towards world health security through advancements in medication-
based and surgical interventions, supported by the success of antimicrobial therapy. The emergence of panresistant 
infectious diseases is becoming a public health problem worldwide. Panresistance is attributable to a complex 
interplay of antimicrobial overuse in healthcare facilities due to lack of regulatory commitment in the backdrop 
of natural mutations in pathogens and rise in immunocompromised hosts. Developing countries are facing the 
brunt in epidemic proportions due to strained public health infrastructure and limited resource allocation to 
healthcare. Panresistance is a biological, behavioural, technical, economic, regulatory and educational problem 
of global concern and combating it will require concerted efforts to preserve the efficacy of the available 
antimicrobials. An intensified commitment needs to be taken up on a war footing to increase awareness in the 
society, increase laboratory capacity, facilitate antimicrobial research, foster emphasis on infection control and 
antimicrobial stewardship, and legislation on manufacturing, marketing and dispensing of antimicrobials.
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Introduction
Infectious diseases of the antiquity such as 
plague, cholera, influenza, smallpox, measles 
and malaria, which have been responsible for 
claiming billions of lives, have either been 
eradicated, eliminated or controlled in various 
parts of the globe due to advanced antimicrobial 
therapeutics and vaccines. The discovery of 
penicillin in 1940s and consequent success at 
wound healing and survival of soldiers in World 
War II was a major breakthrough in the history 
of mankind. The subsequent discovery of a 
series of antimicrobials, some 22 of them cre-
dited to Selman Waksman, brought the menace 
of infectious diseases and ensuing sepsis under 
control. Antimicrobials conferred safety and 
reliability upon a wide variety of diagnostic and 
therapeutic procedures including advanced 
surgeries, organ transplantation and immu-
notherapy, being heavily dependent on anti-
microbial support.
While the era of infectious diseases was 
being considered over, backed upon the 
success of antimicrobial therapy, there was re-
emergence of infectious diseases due to rise in 
immunocompromised populace. The resur-
gence of infectious diseases consequent to 
Human Immunodeficiency Virus (HIV)­Acquired 
Immune Deficiency Syndrome (AIDS) pandemic 
resulted in 1.5 fold increase in infectious di-
seases mortality between 1980 and 1992. HIV-
AIDS became the leading cause of mortality 
amongst infectious diseases in the following 
two decades [1]. Antimicrobial resistance, being 
unanticipated in its entirety, evolved manifolds 
to reach dangerous connotations towards 
panresistance. World Health Organization 
(WHO) theme for World Health Day 2011 was 
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“Antimicrobial resistance: No action today, no 
cure tomorrow” [2]. Since then, despite pro-
gressive steps towards concept development, 
the magnitude of panresistance overshadows 
control efforts [3, 4]. Panresistance is a com-
plete roadblock to years of progress made 
towards advanced healthcare. With infectious 
diseases being the second leading cause of 
mortality worldwide as per global health es-
timates, the day may not be far when it will be 
the leading cause of death due to emergence 
of panresistance emanating the realization of 
a ‘Microbial Holocaust’.
Evolution of panresistance
The rise of panresistance is multifactorial. 
Microbial factors include natural evolution of 
microorganisms conferring increase in viru-
lence, infectivity, pathogenicity and anti-
microbial resistance. Opportunistic pathogens 
are crossing host barriers and are now being 
encountered as emerging pathogens [1, 5, 6, 
7]. Established pathogens are evolving into 
panresistant potentially untreatable mutants 
such as glycopeptide resistant Gram negative 
bacteria, which are resistant to all available 
antimicrobials including tigecycline and colistin. 
In addition, totally drug resistant tuberculosis, 
multidrug resistant malaria and dual osel-
tamivir­adamantane resistant influenza viruses 
are emerging [8]. Tuberculosis has emerged as 
the leading cause of mortality amongst in-
fectious diseases overtaking HIV-AIDS due to 
the development of resistance. Tuberculosis 
related deaths in 2014 were 1.5 million, sur-
passing 1.2 million HIV-AIDS related deaths.
Host factors include steep rise in immu-
nocompromised populace owing to increased 
organ transplants, immunodeficiency disorders, 
neoplasms, old age as well as patients under 
intensive-care. Prescription trend factors inclu-
de aggressive exposure of multiple anti-
microbials to patients harbouring multiresistant 
microorganisms. Rising empiricism in anti-
microbial therapy overshadows susceptibility 
guided therapy, facilitating development of 
resistance due to selection pressure [9, 10]. 
Panresistant microorganisms can spread re-
sistance-conferring mobile genetic elements to 
susceptible microorganisms and commensal 
flora, contributing to the development of a 
reservoir of antimicrobial resistance in human 
body. Panresistant microorganisms can also 
colonize inanimate surfaces and create reser-
voirs from which they can get transmitted in 
healthcare facilities thereby rendering all pa-
tients and healthcare professionals at-risk. 
Human factors involved include a complex 
interplay of antimicrobial misuse in healthcare 
facilities due to lack of regulatory commitment 
in the backdrop of natural mutations which has 
contributed to the development of panresistance 
[1, 3]. Panresistance is increasingly being re-
ported in Gram negative microbes [6, 11]. The 
South and South-East Asia region (SEAR) has 
one of the highest prevalence of tuberculosis 
with one death every few minutes [12]. All forms 
of resistant tuberculosis viz. Multi drug resistant 
tuberculosis (MDR TB), extremely drug resistant 
tuberculosis (XDR TB) and totally drug resistant 
tuberculosis (TDR TB) have been reported. The 
recent reports of TDR TB from Iran, India and 
Italy represent the tip of an iceberg as antitu-
bercular susceptibility testing occurs in only 5% 
patients worldwide [12-15]. The DOTS (Directly 
Observed Treatment Short course) program for 
developing countries has been challenged by 
the emergence of XDR TB and TDR TB not only 
due to resistance but also due to limitations of 
antitubercular susceptibility testing, which is 
offered only at highly specialized centres. A 
seven year study on DOTS plus reported 61% 
cure, 19% deaths, 18% defaulters, 3% failed 
treatments and an average delay of 5 months 
in initiation of therapy [16]. Antimalarial resis-
tance to artemisinin and quinine has been 
 re ported in SEAR and Africa [17, 18]. Antiviral 
resis tance to almost all antivirals has been re-
ported particularly in Hepatitis B, Herpes virus, 
Cytomegalovirus, Varicella zoster, Influenza 
and HIV [19–23].
Impact of panresistance
The emergence of panresistant infectious 
diseases is becoming a public health problem 
worldwide. Developing countries are facing the 
brunt in epidemic proportions due to strained 
public health infrastructure and limited re-
source allocation to healthcare. The rise of 
panresistance is discouraging the development 
of newer antimicrobials under private equity. 
Any new antimicrobial loses economic value in 
a few years due to emergence of resistance 
compared to medicines for lifestyle diseases 
which remain economically rewarding for many 
years [24, 25]. Inadvertent or intended release 
of panresistant bioweapons against humans, 
fauna and flora can wreak havoc leading to 
widespread disruption [26].
The future
Panresistance is a biological, behavioural, 
technical, economic, regulatory and educational 
problem of global concern and combating it 
will require concerted efforts to preserve the 
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efficacy of available antimicrobials. An inten­
sified commitment needs to be taken up on a 
war footing.
Knowledge, Attitude and Practices of General 
Public
Examples from successful programs such 
as “Antibiotics are not Automatic” in France, 
“Get Smart” in the US and “Do Bugs Need 
Drugs?” in Canada need to be followed in 
developing countries [27]. Health educators, 
public health specialists, government officials 
and community leaders should be sensitized 
about the hazards of using antimicrobials. 
There should be active community participation 
in the cause of positive health. Citizens must 
foster sound belief and inculcate positive 
attitude and responsible behaviour in societal 
healthcare system. There is long standing need 
for increasing awareness about approach, ope-
ration, decision making and scope of healthcare 
amongst general population. Attitude and 
expectations need a paradigm shift from 
‘instant cure’ and ‘magic pill’ to ‘rational drug 
therapy’ and ‘evidence based healthcare’. 
Patients should not engage into unjustified 
requests or arguments or frequent change of 
doctor’s advice. Self­medication, quack 
remedies, underdosing and uncompleted 
regimens should be stopped. Left over drugs 
from the last prescription should not be taken 
again for a similarly perceived symptom. The 
society should ensure availability of trained 
pharmacists through legislation to ensure 
adherence to prescription safety.
Hospital Infection Control
Nosocomial pathogens evolve under con-
tinuous selection pressure to become panre-
sistant. Hospital Infection Control involves 
monitoring of hospital safety measures such 
as patient isolation, visitor control, contact 
precautions, barrier nursing, universal pro-
phylaxis, hand hygiene, environmental sur-
veillance and equipment sterilization in ope-
ration theatre, labour room, intensive care, 
oncology, burns, dialysis and transplant 
centres. Carriers are identified, quarantined 
and organisms are eradicated from hospital 
environment. Hand hygiene is considered to be 
the single most important step in controlling 
spread of panresistant pathogens. Compliance 
is limited due to overbearing pressures of 
patient volume, time, undue multitasking and 
paucity of washing infrastructure. Hand wa-
shing with soap followed by antiseptic handrub 
should be strongly encouraged as the standard 
of care for all healthcare practitioners and 
patients. A broad based policy and standards 
for infection control in healthcare facilities 
needs to be implemented. The Jaipur declaration 
on AMR-2011 for SEAR and the Chennai de cla-
ration for India are efforts to this end [25, 28].
Laboratory Surveillance
Laboratory based surveillance of infectious 
diseases, pathogens, susceptibility patterns, 
resistance phenotyping, outbreak investigation, 
hospital environmental surveillance and epi-
demiological typing is mandated to keep a track 
of panresistance development. A number of 
pathogens such as viruses, parasites, certain 
bacteria and fungi surpass identification under 
the constraints of resources available in routine 
labs [1, 5–7]. Antimicrobial susceptibility testing 
for tuberculosis, parasites, viruses and fungi 
are only available in reference labs which are 
far and few. Unavailability of testing facilities 
promotes empirical antimicrobial therapy to 
save the patient, thereby contributing to the 
development of panresistance. Enhancing 
laboratory capacity with automated phenotypic 
identification systems, molecular microbiology 
techniques and biostatistical softwares, precise 
organism identification to species level, anti­
microbial susceptibility patterns, resistance 
phenotypes, typing and data analysis has been 
facilitated. The resistogram generated can be 
used to guide infection control strategies with 
other collaborating centres through a worldwide 
free web repository. The potential of the micro-
biology lab is largely underutilized in developing 
countries due to deficiencies in lab equipment 
and specialized staff.
Antimicrobial Stewardship
Antimicrobial stewardship including antimi-
crobial rotation and holiday, combination 
therapy and Standard Treatment Guidelines 
have proven to be beneficial [29, 30]. A dy-
namic antimicrobial policy should specify as to 
when escalation and de-escalation to reserve 
antimicrobials such as carbapenems, colistin, 
tigecycline, vancomycin, teicoplanin and dap-
tomycin, needs to be undertaken. Spiralling 
empiricism, prophylactic antimicrobial usage 
and attitude to use the best antimicrobial 
should be discouraged and susceptibility 
guided therapy be promulgated [1, 5–7]. Regu-
lar availability of required antimicrobials, pre-
scription audits, formulary restriction, pre-au-
thorization and stop orders should be advo-
cated to ensure policy implementation which 
in turn should be linked to grant of accredita-
tion to hospitals. A multidisciplinary approach 
would include building of consensus across 
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clinicians and arbitration of disagreements. The 
WHO classification of antimicrobials into key, 
watch and reserve groups in Jun 2017 can form 
a guideline towards the successful implementa-
tion of antimicrobial authorization and prescrip-
tion prudence [31].
Health Resource Allocation
The present situation demands an increase 
in resource allocation in the health sector to 
boost healthcare infrastructure, public awa-
reness and accessibility. This would entail 
accommodative policy for establishment of 
specialized medical varsities, superspeciality 
hospitals, specialized laboratories, biocon-
tainment facilities, promotion of antimicrobial 
research through grants, medical journals, 
medical societies, involvement of private sector 
through public private partnership and mass 
health campaigns. Comprehensive standards 
for surveillance and control should be estab-
lished in association with international health 
regulations [32]. National surveillance systems 
similar to the National Nosocomial Infection 
Surveillance (NNIS) in the US and SENTRY 
Antimicrobial Surveillance Program can be 
instituted [32].
Antimicrobial Research
Research on the development of newer 
antimicrobials has multipronged implications. 
One, effective antimicrobials would foster 
prompt treatment of infections caused by 
resistant pathogens and prevent progression 
to disseminated infection and sepsis. Two, 
successful therapy will reduce transmission of 
resistant pathogens. Three, chemoprophylaxis 
can be directed for prevention of infections in 
susceptible host population. Four, behavioural 
research regarding non-adherence to pre-
scribed drug schedules and self-medication are 
social issues in which there has been limited 
research. Research needs to be undertaken on 
these behavioural factors, so that targeted 
intervention can be planned for bringing about 
changes at the societal level.
Public Health Measures
Robust public health infrastructure and 
human resource with strengthened vector 
control programs, immunization coverage, 
screening programs, national health programs, 
rapid outbreak investigation, quarantine and 
control measures are required. Panresistant 
infectious diseases and resistant pathogens 
should be made notifiable. Effective public 
health will reduce reliance on antimicrobials 
and break chain of transmission of resistant 
microbes [25].
Legislation on Manufacturing, Marketing and 
Dispensing of Antimicrobials
Three important areas of intervention exist 
at manufacturing, marketing and dispensing 
of antimicrobials. Quality assurance in anti-
microbial dosage and efficacy from manufac­
turers and ethical marketing can have profound 
downstream effects. While regulation regarding 
prohibition of sale of antimicrobials without 
proper prescriptions is in place, it is not being 
implemented. Regulatory mechanisms for en-
suring good manufacturing practices, respon-
sible marketing and dispensation by phar-
macists need to be instituted and strengthened 
through industrial and marketing audit, and 
enhanced vigil on pharmacies. Antimicrobial 
and infection control advisory bodies need to 
be actively involved to integrate surveillance 
and legislation.
Role of WHO
WHO has issued a call for action to halt the 
spread of AMR by introducing a six-point policy 
package for all countries to combat AMR. This 
includes commitment to a comprehensive, 
financed national plan with accountability and 
civil society engagement; strengthening of 
surveillance and laboratory capacity; ensuring 
uninterrupted access to essential medicines of 
assured quality; regulation and promotion of 
rational use of medicines, including in animal 
husbandry, and ensuring proper patient care; 
reduction of antimicrobials usage in food-pro-
ducing animals; enhancing infection prevention 
and control; and fosterage of innovations and 
research and development for new tools [2]. 
WHO has also laid down the procedure to 
establish national laboratory based surveillance 
including identification of pathogens and 
diseases of public health importance, creation 
of network of Antimicrobial Susceptibility 
Testing (AST) and standardization of involved 
methodologies. World bodies such as Asso-
ciation for Prudent Use of Antimicrobials 
(APUA) and World Alliance against Antibiotic 
Resistance (WAAR) are efforts to this end [33]. 
WHO has advocated a priority pathogens list in 
2017 to highlight a list of bacteria for which 
newer antimicrobials are urgently required [34]. 
WHO has classified antimicrobials into key 
access, watch group and reserve group to opti-
mize usage guidelines worldwide [35].
Conclusions
Panresistance is emerging in alarming 
proportions worldwide, thereby threatening 
the advances made towards public health 
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security of the world. There is a dire need to 
identify this threat, develop concerted 
multipronged strategy, develop infrastructure, 
foster expertise and take coordinated and 
urgent steps to tackle the serious public health 
challenge. It is time for action else we face the 
consequences of microbial genocide of 
mankind. Resolute conviction towards astute 
measures with a sustained momentum will hold 
a promise for safeguarding health of future 
generations.
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